Circle Four Pharmaceutical (00460.HK): Huisheng Bio's self-developed GLP-1R/GCGR dual-target innovative drug P052 injection granted IND approval.

Zhijun Finance APP news, Four Rings Medicine (00460.HK) announced that its non-wholly-owned subsidiary Huisheng Biopharmaceutical Co., Ltd. (Huisheng Bio) has obtained implicit approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) for the clinical trial application (IND) of the innovative drug P052 injection developed independently by the company, which is a dual-target agonist of glucagon-like peptide-1 receptor (GLP-1R) / glucagon receptor (GCGR) used for the treatment of type 2 diabetes, overweight or obesity.